We evaluated the effectiveness and safety of intralesional meglumine antimoniate (MA) in
24 not submitted to previous treatment patients with cutaneous leishmaniasis (CL) and with …

Cutaneous leishmaniasis (CL) is a high-morbidity, vector-borne disease endemic to
Colombia. Unlike conventional systemic antileishmanial therapy, intralesional meglumine …

Cutaneous leishmaniasis (CL) is not a life-threatening condition. However, its treatment can
cause serious adverse effects and may sometimes lead to death. Recently, safer local …

Although intralesional meglumine antimoniate (MA) infiltration is considered an option for
cutaneous leishmaniasis (CL) therapy and is widely used in the Old World, there have been …

INTRODUCTION: Intralesional treatment for cutaneous leishmaniasis has been applied for
over 30 years at the Oswaldo Cruz Foundation, Rio de Janeiro, with good therapeutic results …

One hundred and four patients with a clinical diagnosis of cutaneous leishmaniasis (CL) and
a positive Giemsa‐stained smear for the parasite were recruited after informed consent into …

BACKGROUND Cutaneous leishmaniasis (CL) is a world-wide health problem which
currently lacks effective, affordable and easy to use therapy. Recently, the meglumine …

Background Meglumine antimoniate (MA) remains the main treatment for cutaneous
leishmaniasis (CL). Uncontrolled studies suggest that intralesional MA (IL-MA) may be …

We conducted a quasi-experimental study to compare the response to meglumine
antimoniate in patients with localized cutaneous leishmaniasis from two endemic areas of …

Abstract Although New World cutaneous leishmaniasis is not itself a life-threatening
disease, its treatment with systemic antimonials can cause toxicity that can be dangerous to …